Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from the first double-blind, placebo-controlled clinical study to evaluate exenatide injection ...

No evidence seen to support GLP-1 receptor agonist exenatide as disease-modifying treatment for Parkinson disease. HealthDay News — The glucagon-like peptide-1 receptor agonist exenatide does not ...

FRIDAY, Feb. 7, 2025 (HealthDay News) -- The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, according to a study published ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Previous studies suggest GLP-1 receptor agonists may ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. The world's largest and longest trial ...

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up. The US Food and Drug Administration (FDA) has ...

Vivani Medical began the LIBERATE-1 trial, testing a six-month exenatide implant for chronic weight management in Australia. The study uses NanoPortal technology, with results expected in mid-2025 and ...

Appointment comes as Vivani prioritizes the development of its GLP-1 implants for the treatment of obesity and chronic weight management Under Bradbury’s leadership as CEO, Amylin Pharmaceuticals, ...

Wednesday, Vivani Medical Inc (NASDAQ:VANI) released preclinical data on weight loss effects for NPM-115, the company’s miniature, twice-yearly exenatide subdermal implant under development for ...

For type 2 patients, the use of GLP-1 agonists (such as Victoza and Byetta) can often lead to significant improvements in blood glucose control and weight loss with little risk for hypoglycemia.